- Home
- NBN vs PHAR Comparison
NBN vs PHAR Comparison
Compare NBN & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBN
- PHAR
- Stock Information
- Founded
- NBN 1872
- PHAR 1988
- Country
- NBN United States
- PHAR Netherlands
- Employees
- NBN N/A
- PHAR N/A
- Industry
- NBN Major Banks
- PHAR Biotechnology: Pharmaceutical Preparations
- Sector
- NBN Finance
- PHAR Health Care
- Exchange
- NBN Nasdaq
- PHAR Nasdaq
- Market Cap
- NBN 811.6M
- PHAR 951.7M
- IPO Year
- NBN N/A
- PHAR N/A
- Fundamental
- Price
- NBN $95.69
- PHAR $14.55
- Analyst Decision
- NBN Hold
- PHAR Strong Buy
- Analyst Count
- NBN 1
- PHAR 3
- Target Price
- NBN $115.00
- PHAR $30.00
- AVG Volume (30 Days)
- NBN 95.3K
- PHAR 14.4K
- Earning Date
- NBN 10-28-2025
- PHAR 10-23-2025
- Dividend Yield
- NBN 0.04%
- PHAR N/A
- EPS Growth
- NBN 32.98
- PHAR N/A
- EPS
- NBN 10.08
- PHAR N/A
- Revenue
- NBN $204,086,000.00
- PHAR $339,836,000.00
- Revenue This Year
- NBN $17.75
- PHAR $17.44
- Revenue Next Year
- NBN $9.91
- PHAR $8.46
- P/E Ratio
- NBN $9.48
- PHAR N/A
- Revenue Growth
- NBN 33.67
- PHAR 22.44
- 52 Week Low
- NBN $75.29
- PHAR $7.31
- 52 Week High
- NBN $113.01
- PHAR $17.08
- Technical
- Relative Strength Index (RSI)
- NBN 35.11
- PHAR 51.90
- Support Level
- NBN $93.45
- PHAR $13.18
- Resistance Level
- NBN $111.22
- PHAR $16.29
- Average True Range (ATR)
- NBN 3.07
- PHAR 0.55
- MACD
- NBN -1.65
- PHAR -0.04
- Stochastic Oscillator
- NBN 10.84
- PHAR 44.05
About NBN Northeast Bank
Northeast Bank provides banking and financial services to individual and corporate customers in the United States. The firm conducts its loan-related activities through two primary channels: the Community Banking Division, and the Small Business Administration (SBA) National Division. Its loan portfolio comprises residential mortgage loans; multi-family and other commercial real estate loans; commercial and industrial loans, consumer loans, and small business administration loans. The firm also provides telephone banking, online banking, mobile banking, and remote deposit capture services. The revenue of the company is derived principally from interest and dividends from the bank.
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.